Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study

详细信息    查看全文

• 作者：Mari-Anne Rowlands (1)
  Kate Tilling (1)
  Jeff M. P. Holly (2)
  Chris Metcalfe (1)
  David Gunnell (1)
  Athene Lane (1)
  Michael Davis (1)
  Jenny Donovan (1)
  Freddie Hamdy (3)
  David E. Neal (4)
  Richard M. Martin (1) (5)
  
• 关键词：Insulin ; like growth factors ; Active monitoring ; Prostate ; specific antigen ; Localized prostate cancer ; Prognosis
• 刊名：Cancer Causes and Control
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：24
• 期：1
• 页码：39-45
• 全文大小：200KB
• 参考文献：1. National Institute for Health and Clinical Excellence (2008) Prostate cancer diagnosis and treatment CG58. National Institute for Health and Clinical Excellence, London
  2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, Eastham JA, Enke CA, Farrington TF, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC. The NCCN clinical practice guidelines in oncology for prostate cancer V.3.2012. Accessed 1 June 2012
  3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-16 CrossRef
  4. van den Bergh RCN, Roemeling S, Roobol MJ, Wolters T, Schroder FH, Bangma CH (2008) Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer—a review. Eur Urol 54:505-16 CrossRef
  5. Martin RM, Gunnell D, Hamdy F, Neal DE, Lane A, Donovan J (2006) Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol 176:439-49 CrossRef
  6. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-527 CrossRef
  7. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-28 CrossRef
  8. Mita K, Nakahara M, Usui T (2000) Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. Int J Urol 7:321-29 CrossRef
  9. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr (2001) Hsing AW: insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10:421-27
  10. Rowlands MA, Holly JMP, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD, Martin RM (2012) Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study protect. Cancer Res 72:503-15 CrossRef
  11. Rowlands MA, Holly J, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal D, Martin R (2012) Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 23:347-54 CrossRef
  12. Ho PJ, Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 46:333-42 CrossRef
  13. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM (2002) Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20:833-41 CrossRef
  14. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JMP (2007) IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26:5966-972 CrossRef
  15. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JKV, Sawyers CL (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3?K/Akt pathway activation in glioblastoma and prostate cancer. PNAS 104:5563-568 CrossRef
  16. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291-296
  17. Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Ciftcioglu A, Gulkesen KH, Ozes NO, Baykara M, Luleci G, Sanlioglu S (2004) The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncology 22:307-12 CrossRef
  18. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and protect studies. Eur J Cancer 46:3095-101 CrossRef
  19. Ohori M, Wheeler TM, Scardino PT (1994) The new American joint committee on cancer and international union against cancer TNM classification of prostate cancer. Cancer 74:104-14 CrossRef
  20. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D (2003) Serum insulin-like growth factor I: tumor marker or etiologic factor? a prospective study of prostate cancer among Finnish men. Cancer Res 63:3991-994
  21. Vergis R., Van As N, Foo K, Venkitaraman R, Norman AR, Holly JM, Huddart RA, Horwich A, Dearnaley DP, Parker CC (2007) Serum IGF-1 and IGFBP-3 as biomarkers of progression in untreated, localized prostate cancer. ASCO 2007 Prostate Cancer Symposium
  22. Johansson M, McKay JD, Rinaldi S, Wiklund F, Adami HO, Gronberg H, Kaaks R (2009) Stattin P+: genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate 69:1281-291 CrossRef
  23. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-383 CrossRef
  24. Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA (2012) Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents. Cancer 118:1533-542 CrossRef
  25. McLaren DB, McKenzie M, Duncan G, Pickles T (1998) Watchful waiting or watchful progression? Cancer 82:342-48 CrossRef
  26. O’Brien MF, Cronin AM, Fearn PA, Savage CJ, Smith B, Stasi J, Scardino PT, Fisher G, Cuzick J, Moller H, Oliver RT, Berney DM, Foster CS, Eastham JA, Vickers AJ, Lilja H (2011) on behalf of the Trans-Atlantic Prostate Group: evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 128:2373-381 CrossRef
  27. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810-816 CrossRef
  
• 作者单位：Mari-Anne Rowlands (1)
  Kate Tilling (1)
  Jeff M. P. Holly (2)
  Chris Metcalfe (1)
  David Gunnell (1)
  Athene Lane (1)
  Michael Davis (1)
  Jenny Donovan (1)
  Freddie Hamdy (3)
  David E. Neal (4)
  Richard M. Martin (1) (5)
  
  1. School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK
  2. School of Clinical Sciences North Bristol, University of Bristol, Bristol, BS10 5NB, UK
  3. Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, OX3 9DU, UK
  4. Department of Oncology, University of Cambridge, Box 279 (S4), Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK
  5. MRC Centre for Causal Analysis in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK
  
• ISSN：1573-7225

文摘

Purpose Active monitoring of prostate cancer requires the selection of low-risk cancers and subsequent identification of disease progression. Our objective was to determine whether serum insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2 or IGFBP-3 at diagnosis (potential biomarkers of prognosis), and repeated measures of IGFBP-2 (potential biomarker of tumour growth), were associated with annual change in PSA and PSA doubling time (PSADT), proxies for disease progression. Methods We investigated associations of circulating IGFs and IGFBPs with PSA measures using multilevel models, in 909 men (recruited between 1999 and 2009) with PSA-detected clinically localized prostate cancer undergoing active monitoring in the United Kingdom. Each man had an average of 14 measurements of PSA during a mean of 4-year follow-up. Results IGF-I, IGF-II, IGFBP-2, and IGFBP-3 were not associated with baseline PSA. There was weak evidence that IGF-I at diagnosis was positively associated with a rapid post-diagnosis PSADT (??years vs. >4?years): OR 1.34 (95?% CI 0.98, 1.81) per SD increase in IGF-I. IGFBP-2 increased by 2.1?% (95?% CI 1.4, 2.8) per year between 50 and 70?years, with no association between serial IGFBP-2 levels and PSADT. There was no evidence that serum IGF-II, IGFBP-2, or IGFBP-3, or post-diagnosis IGFBP-2, were associated with PSA kinetics in men with PSA-detected localized prostate cancer. Conclusions The weak association of IGF-I with PSADT requires replication in larger datasets, and more definitive evidence will be provided on the maturity of long-term active monitoring cohorts with relevant clinical outcomes (metastasis and prostate cancer mortality).